研究了N 7-(2-脱氧-β-D-赤型戊呋喃糖基)鸟嘌呤(N 7 G d;1)的碱基配对性质。通过核苷碱基阴离子糖基化获得核苷1。研究了各种6-烷氧基嘌呤-2-胺3a - i与2-脱氧-3,5-二-O-(4-甲苯甲酰基)-α-D-赤型-戊呋喃糖酰氯的糖基化反应(8)。所述Ñ 9 / Ñ 7 -glycosylation比率被发现是1:1时6- isopropoxypurin -2-胺(3D),而6-(2-甲氧基乙氧基)嘌呤-2-亚胺(3i)主要产生N 9-核苷(2:1)。通过固相合成制备含有化合物1的寡核苷酸,并将其与具有四个与N 7 G d相对的常规核苷的互补链杂交。根据双链形成的T m值和焓数据,提出了N 7 G d和dG之间的碱基对。从可能的N 7 G d dG碱基对动机出发,Hoogsteen配对可以被排除,因为7-脱氮基2'-脱氧鸟苷与N 7 G d形成与dG相同的稳定碱基对。
研究了N 7-(2-脱氧-β-D-赤型戊呋喃糖基)鸟嘌呤(N 7 G d;1)的碱基配对性质。通过核苷碱基阴离子糖基化获得核苷1。研究了各种6-烷氧基嘌呤-2-胺3a - i与2-脱氧-3,5-二-O-(4-甲苯甲酰基)-α-D-赤型-戊呋喃糖酰氯的糖基化反应(8)。所述Ñ 9 / Ñ 7 -glycosylation比率被发现是1:1时6- isopropoxypurin -2-胺(3D),而6-(2-甲氧基乙氧基)嘌呤-2-亚胺(3i)主要产生N 9-核苷(2:1)。通过固相合成制备含有化合物1的寡核苷酸,并将其与具有四个与N 7 G d相对的常规核苷的互补链杂交。根据双链形成的T m值和焓数据,提出了N 7 G d和dG之间的碱基对。从可能的N 7 G d dG碱基对动机出发,Hoogsteen配对可以被排除,因为7-脱氮基2'-脱氧鸟苷与N 7 G d形成与dG相同的稳定碱基对。
Resistance-Modifying Agents. 8. Inhibition of <i>O</i><sup>6</sup>-Alkylguanine-DNA Alkyltransferase by <i>O</i><sup>6</sup>-Alkenyl-, <i>O</i><sup>6</sup>-Cycloalkenyl-, and <i>O</i><sup>6</sup>-(2-Oxoalkyl)guanines and Potentiation of Temozolomide Cytotoxicity in Vitro by <i>O</i><sup>6</sup>-(1-Cyclopentenylmethyl)guanine
作者:Roger J. Griffin、Christine E. Arris、Christine Bleasdale、F. Thomas Boyle、A. Hilary Calvert、Nicola J. Curtin、Christine Dalby、Sreenivas Kanugula、Nicola K. Lembicz、David R. Newell、Anthony E. Pegg、Bernard T. Golding
DOI:10.1021/jm000961o
日期:2000.11.1
A series of O-6-allyl- and O-6-(2-oxoalkyl)guanines were synthesized and evaluated, in comp ari son with the corresponding O-6-alkylguanines, as potential inhibitors of the DNA-repair protein O-6-alkylguanine-DNA alkyltransferase (AGT). Simple O-6-alkyl- and O-6-cycloalkylguanines were weak AGT inactivators compared with O-6-allylguanine (IC50 = 8.5 +/- 0.6 muM) With IC50 values ranging from 100 to 1000 muM. The introduction of substituents at C-2 of the allyl group of O-6-allylguanine reduced activity compared with the parent compound, while analogous compounds in the O-6-(2-oxoalkyl)guanine series exhibited very poor activity (150-1000 muM) O-6-Cycloalkenylguanines proved to be excellent AGT inactivators, with 1-cyclobutenylmethylguanine (IC50 = 0.55 +/- 0.02 muM) and 1-cyclopentenylmethylguanine (IC50 = 0.39 +/- 0.04 muM) exhibiting potency approaching that of the benchmark AGT inhibitor O-6-benzylguanine (IC50 = 0.18 +/- 0.02 muM). 1-Cyclopentenylmethylguanine also inactivated AGT in intact HT29 human colorectal carcinoma cells (IC50 = 0.20 +/- 0.07 muM) and potentiated the cytotoxicity of the monomethylating antitumor agent Temozolomide by approximately 3- and 10-fold, respectively, in the HT29 and Colo205 tumor cell lines. The observation that four mutant AGT enzymes resistant to O-6-benzylguanine also proved strongly cross-resistant to 1-cyclopentenylmethylguanine indicates that the O-6-substituent of each compound makes similar binding interactions within the active site of AGT.